Large companies participating in the bio-economy are replacing traditional processes and technologies with automated workflows and AI-driven optimization techniques. This modern approach has opened the door for a radical transformation of biology and a rapid expansion of potential applications. This increased demand requires a secure, scalable, interoperable, protocol-driven platform that can accommodate multiple users working on various projects across geographically distributed organizations. These new approaches are pushing companies to update their product development methods and IP strategies to maintain their competitive advantage.
TeselaGen is deploying the first solution that incorporates state-of-the-art design automation technology for biotechnology as a secure enterprise operating system. We make the development of bio-based products faster and easier by providing a highly secure enterprise software platform that our customers can use immediately, instead of spending millions to develop it themselves. In addition to our enterprise solutions, we offer open-access tools that can be utilized by any company, regardless of size, to streamline their biotechnology processes.
By working with TeselaGen, biotech companies can replace costly and time-consuming traditional methods for developing biotech products in pharma, ag-tech, and industrial biotech with a data-driven platform. This platform enables the development of new high-performance bioproducts faster than ever before. For example, Protein Evolution has used the TeselaGen platform to develop enzymes that can transform polyester waste into a reusable resource, significantly saving years of development time. Lanzatech uses our platform to accelerate and enhance the success rate of complex biological designs and combinatorial assemblies. Meanwhile, Microbyre has used our platform to establish new model organisms for fermentation by creating a high-throughput prokaryotic phenotyping and domestication pipeline and using our capabilities to develop and troubleshoot plasmid designs and re-cloning, thus reducing R&D costs.